Jinhai Medical Technology Names Li Bin Executive Director and Co-Chairman

Jinhai International Group Holdings Limited ( (HK:2225) ) has issued an update.

Jinhai Medical Technology Limited has appointed Li Bin as an executive director and co-chairman of the board with effect from 3 February 2026, strengthening its leadership with a veteran who holds a significant equity interest of 40 million shares in the company. Li brings more than 20 years of enterprise and business management experience in the in vitro diagnostics sector, including founding and leading Shanghai Anbaida Investment Management Consulting Co., Ltd. and serving as a first-tier distributor for Roche In Vitro Diagnostics in Shanghai; under a three-year service contract, he will receive a fixed director’s fee of HK$200,000 per month, a move that underscores the group’s effort to deepen industry expertise and governance as it advances its medical diagnostics business.

The most recent analyst rating on (HK:2225) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

More about Jinhai International Group Holdings Limited

Jinhai Medical Technology Limited is a Hong Kong-listed medical technology group focused on in vitro diagnostic (IVD) products, including diagnostic reagents and related solutions for clinical and laboratory use. The company operates through subsidiaries and works with major global IVD brands via distribution and sales arrangements in key markets such as Shanghai and the broader Greater China region.

Average Trading Volume: 8,783,473

Technical Sentiment Signal: Buy

Current Market Cap: HK$11.06B

For detailed information about 2225 stock, go to TipRanks’ Stock Analysis page.